Syra Health Corp. reports news as an integrated healthcare solutions company serving government, public-sector, and commercial healthcare organizations. Its updates center on prevention-focused and access-oriented solutions, including Population Health programs, healthcare analytics, HIPAA-compliant digital health tools, health education, training, and healthcare workforce solutions.
Recurring company developments include quarterly and annual financial results, margin and profitability trends, Population Health revenue growth, customer demand from state health departments and private-sector organizations, and cost-management initiatives. Syra Health also reports governance and leadership changes, information-security milestones such as ISO 27001:2022 certification, and operating risks tied to government healthcare budgets and contract timing.
Syra Health Corp. (SYRA) announced that its Board of Directors is initiating a national search for a new Chief Executive Officer to replace current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO during the transition period and is expected to remain part of the leadership team after the appointment of her successor.
This leadership transition is described as part of a strategic succession plan aimed at positioning the healthcare technology company for its next growth phase. The Board emphasized its commitment to finding a leader who will advance the company's mission of delivering accessible, affordable, and prevention-focused healthcare solutions.
Syra Health (OTCQB: SYRA), a healthcare technology company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results. Investors can access the conference call via webcast through the company's investor relations website and submit questions via email. A replay of the webcast will be available in the investors section of Syra Health's website.
Syra Health Corp. (NASDAQ: SYRA) has announced its voluntary delisting from the Nasdaq Capital Market, with the last trading day expected around April 21, 2025. The decision follows the company's non-compliance with Nasdaq's minimum $1.00 bid price requirement, which was notified on October 18, 2024.
The healthcare technology company plans to file Form 25 with the SEC around April 11, 2025. Management views this as a strategic pause to focus on strengthening core fundamentals and reducing Nasdaq-associated costs. The company expects its common stock to transition to the OTC market and intends to maintain shareholder communication, though trading continuity is not guaranteed.
Syra Health (NASDAQ: SYRA) has secured a one-year, $660,000 Population Health contract extension with a national healthcare organization, bringing the total contract value to $1.32 million over two years.
The extension involves providing Healthcare Effectiveness Data and Information Set (HEDIS®) outreach and support services, focusing on improving healthcare quality, enhancing member outcomes, and reducing costs through data analysis and member outreach initiatives.
This renewal represents a continuation of services initially announced in March 2024 and supports the expansion of Syra Health's Population Health business unit, which is identified as a key growth contributor to the company's diversifying revenue base through higher-margin business segments.
Syra Health (NASDAQ: SYRA) reported strong financial results for FY2024, with revenue reaching $8.0 million, up 45% from $5.5 million in 2023. The company's Population Health segment showed remarkable growth, with revenues more than doubling to $1.7 million, while Healthcare Workforce revenue increased 38% to $5.9 million.
Q4 2024 showed significant operational improvements, with net losses nearly halving to ($504,000) from ($995,000) in Q4 2023, and operating expenses decreasing 39% YoY. The company maintained a strong balance sheet with $2.4 million in cash and no long-term debt as of December 31, 2024.
For 2025, Syra Health projects low double-digit percentage revenue growth, driven by higher-margin Population Health and Behavioral Health units. Recent achievements include positive preliminary results from the Syrenity app clinical study and several new contract wins and extensions with government agencies.
Syra Health (NASDAQ: SYRA), a healthcare technology company, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 11, 2025, before market opening. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results.
Investors can access the conference call via webcast through the company's investor relations website. Those interested in submitting questions for the call can email them to corbin@haydenir.com. A replay of the webcast will be available in the investors section of Syra Health's website.
Syra Health Corp. (NASDAQ: SYRA) has secured a $450,000 contract extension with the Shelby County Health Department in Tennessee. This one-year extension allows Syra Health's team of epidemiologists and biostatisticians to continue their work identifying disease trends and assessing economic impacts, as initially announced in February 2024.
The project involves data analytics and the development of a public-facing dashboard providing real-time insights. With an additional one-year renewal option in 2026, the total potential contract value reaches $1.3 million over three years.
This extension represents growth in Syra Health's Population Health business unit, which the company identifies as a key driver of revenue growth. The contract aligns with Syra's strategy to diversify revenue streams across higher-margin business units. According to Dr. Deepika Vuppalanchi, Chair and CEO, the positive demand for their population health solutions demonstrates their ability to improve health outcomes while focusing on long-term revenue growth and value creation.
Syra Health (NASDAQ: SYRA) announced positive preliminary results from a clinical research study of its mental health app, Syrenity, conducted by Indiana University. The randomized study involved 135 participants with moderate or severe depression symptoms, with 63 given access to Syrenity and 72 without.
The six-week study showed promising trends in reducing depression symptoms among Syrenity users compared to non-users. Improvements were noted in cognitive reappraisal and emotion expression. The study population consisted of approximately two-thirds women, 30% racial-ethnic minorities, and 50% with bachelor's degrees or higher.
According to Dr. Lorenzo-Luaces, principal investigator, Syrenity is among less than 5% of mental health apps based on science and uniquely addresses multiple mental health conditions. A second clinical study is planned to test statistical significance, with results intended for publication in a scientific journal.
Syra Health (NASDAQ: SYRA) has secured a new $135,000, six-month contract with a Midwest university to develop behavioral health virtual training modules. The company will create up to 60-minute interactive modules focused on prevention, working alongside university committees and subject matter experts.
Additionally, Syra Health has begun implementing training for healthcare professionals in home and community-based settings through its contract with Indiana's Division of Disability and Rehabilitative Services. The combined value of these training agreements reaches $4.9 million over four years, with both contracts including two optional one-year renewals.